Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a major managed Medicare agreement for TONMYA (cyclobenzaprine HCl sublingual tablets), adding approximately 9 million Medicare beneficiaries effective Jan. 1, 2027. Combined with previously announced commercial coverage agreements and broad Medicaid availability, the company said TONMYA will have pharmacy coverage reaching approximately 145 million covered lives, or 46% of the U.S. covered market, while discussions with additional commercial and Medicare payers continue.
The expanded coverage marks a significant milestone for Tonix, which is positioning TONMYA as a first-in-class, non-opioid treatment option for fibromyalgia. Following the positive launch metrics and expanded coverage, Tonix plans to add 50 sales representatives by mid-third quarter 2026, increasing its commercial sales force to approximately 150 people. The company is also expanding marketing and medical affairs initiatives to increase awareness of TONMYA among healthcare providers and patients.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA, the company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra.
Beyond TONMYA, Tonix is advancing a pipeline of CNS and immunology programs. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Its CNS portfolio also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In immunology, Tonix is developing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The expanded Medicare coverage and planned sales force expansion underscore Tonix’s commitment to broadening access to TONMYA. With 145 million covered lives, the company is well-positioned to capture a significant share of the fibromyalgia market, which has lacked new treatment options for over a decade. The announcement also highlights the growing recognition of non-opioid therapies for chronic pain conditions, aligning with public health efforts to reduce opioid dependence.
For more information, visit the company’s newsroom at https://ibn.fm/TNXP.
